A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats

Neuropharmacology

Volumn 82, Issue , 2014, Pages 41-48

  Koshy Cherian, Ajeesh ^a   Gritton, Howard ^a   Johnson, David E ^b   Young, Damon ^b   Kozak, Rouba ^b   Sarter, Martin ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b PFIZER INC   (United States)

Author keywords

Cognition; KAT II; Kynurenic acid; l Kynurenine; PF 04859989; Schizophrenia

Indexed keywords

ENZYME INHIBITOR; KYNURENIC ACID; KYNURENINE AMINOTRANSFERASE; KYNURENINE AMINOTRANSFERASE II INHIBITOR; NICOTINE; PF 04859989; UNCLASSIFIED DRUG; AMINOTRANSFERASE; CENTRAL NERVOUS SYSTEM AGENTS; GLUTAMIC ACID; KYNURENINE; KYNURENINE-OXOGLUTARATE TRANSAMINASE; NICOTINIC AGENT; PF-04859989; POTASSIUM CHLORIDE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CALIBRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL DESIGN; GLUTAMATERGIC NEUROTRANSMISSION; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; MALE; MEDIAL PREFRONTAL CORTEX; MICROELECTRODE; MOLECULAR DYNAMICS; NERVE CELL MEMBRANE STEADY POTENTIAL; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NERVOUS SYSTEM PARAMETERS; NEUROTRANSMISSION; NICOTINE EVOKED GLUTAMATERGIC TRANSIENT; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; MEMBRANE POTENTIAL; METABOLISM; MICRODIALYSIS; PHYSIOLOGY; SPRAGUE DAWLEY RAT; WISTAR RAT;

ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; ENZYME INHIBITORS; GLUTAMIC ACID; KYNURENIC ACID; KYNURENINE; MALE; MEMBRANE POTENTIALS; MICRODIALYSIS; MICROELECTRODES; NICOTINE; NICOTINIC AGONISTS; POTASSIUM CHLORIDE; PREFRONTAL CORTEX; PYRAZOLES; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; TRANSAMINASES;

EID: 84897510238     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.03.004     Document Type: Article

References (37)

1. C.O. Akagbosu, G.C. Evans, D. Gulick, R.F. Suckow, and D.J. Bucci Exposure to kynurenic acid during adolescence produces memory deficits in adulthood Schizophr. Bull. 38 2010 769 778
2. E.X. Albuquerque, and R. Schwarcz Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges Biochem. Pharmacol. 85 2013 1027 1032
3. K.S. Alexander, J.M. Brooks, M. Sarter, and J.P. Bruno Disruption of mesolimbic regulation of prefrontal cholinergic transmission in an animal model of schizophrenia and normalization by chronic clozapine treatment Neuropsychopharmacology 34 2009 2710 2720
4. K.S. Alexander, A. Pocivavsek, -Q. Wu, L. Pershing, R. Schwarcz, and P. Bruno Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine Neuroscience 238 2013 19 28
5. K.S. Alexander, H.Q. Wu, R. Schwarcz, and J.P. Bruno Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine Psychopharmacology 220 2012 627 637
6. L. Amori, -Q. Wu, M. Marinozzi, R. Pellicciari, P. Guidetti, and R. Schwarcz Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum Neuroscience 159 2009 196 203
7. J.M. Brooks, M.L. Pershing, M.S. Thomsen, J.D. Mikkelsen, M. Sarter, and J.P. Bruno Transient inactivation of the neonatal ventral hippocampus impairs attentional set-shifting behavior: reversal with an α7 nicotinic agonist Neuropsychopharmacology 37 2012 2476 2486
8. A.C. Chess, K. Simoni, E. Alling, and D.J. Bucci Elevations of endogenous kynurenic acid produce spatial working memory deficits Schizophr. Bull. 33 2007 797 804
9. A.C. Chess, A.M. Landers, and D.J. Bucci l-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning Behav. Brain Res. 201 2009 325 331
10. J.A. Dickinson, J.N. Kew, and S. Wonnacott Presynaptic alpha 7- and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms Mol. Pharmacol. 74 2008 348 359
11. A.B. Dounay, M. Anderson, B.M. Bechle, E. Evrard, X. Gan, J.-Y. Kim, L.A. McAllister, J. Pandit, S. Rong, M.A. Salafia, J.B. Tuttle, L.E. Zawadzke, and P.R. Verhoest PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency Bioorg. Med. Chem. Lett. 23 2013 1961 1966
12. S. Erhardt, L. Schwieler, L. Nilsson, K. Linderholm, and G. Engberg The kynurenic acid hypothesis of schizophrenia Physiol. Behav. 92 2007 203 209
13. K. Guillem, B. Bloem, R.B. Poorthuis, M. Loos, A.B. Smit, U. Maskos, S. Spijker, and H.D. Mansvelder Nicotinic acetylcholine receptor β2 subunits in the medial prefrontal cortex control attention Science 333 2011 888 891
14. K.N. Hascup, E.R. Hascup, F. Pomerleau, P. Huettl, and G.A. Gerhardt Second-by-second measures of l-glutamate in the prefrontal cortex and striatum of freely moving mice J. Pharmacol. Exp. Ther. 324 2008 725 731
15. M.E. Hasselmo, and M. Sarter Modes and models of forebrain cholinergic neuromodulation of cognition Neuropsychopharmacology 36 2011 52 73
16. C. Hilmas, E.F. Pereira, M. Alkondon, A. Rassoulpour, R. Schwarcz, and E.X. Albuquerque The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications J. Neurosci. 21 2001 7463 7473
17. M.W. Howe, A.S. Berry, F. Francois, G. Gilmour, J.M. Carp, M. Tricklebank, C. Lustig, and M. Sarter Prefrontal cholinergic mechanisms instigating shifts from monitoring for cues to cue-guided performance: converging electrochemical and fMRI evidence from rats and humans J. Neurosci. 33 2013 8742 8752
18. A. Konradsson-Geuken, C.R. Gash, K. Alexander, F. Pomerleau, P. Huettl, G.A. Gerhardt, and J.P. Bruno Second-by-second analysis of alpha 7 nicotine receptor regulation of glutamate release in the prefrontal cortex of awake rats Synapse 63 2009 1069 1082
19. A. Konradsson-Geuken, H.Q. Wu, C.R. Gash, K.S. Alexander, A. Campbell, Y. Sozeri, R. Pellicciari, R. Schwarcz, and J.P. Bruno Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry Neuroscience 169 2010 1848 1859
20. E.K. Lambe, M.R. Picciotto, and G.K. Aghajanian Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex Neuropsychopharmacology 28 2003 216 225
21. R. Linderholm, E. Skogh, K. Olsson, -L. Dahl, M. Holtze, G. Engberg, M. Samuelsson, and S. Erhardt Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia Schizophr. Bull. 38 2012 426 432
22. B.K. Lipska, N.D. Halim, P.N. Segal, and D.R. Weinberger Effects of reversible inactivation of the neonatal ventral hippocampus on behavior in the adult rat J. Neurosci. 22 2002 2835 2842
23. P.D. Livingstone, J.A. Dickinson, J. Srinivasan, J.N. Kew, and S. Wonnacott Glutamate-dopamine crosstalk in the rat prefrontal cortex is modulated by alpha7 nicotinic receptors and potentiated by PNU-120596 J. Mol. Neurosci. 40 2010 172 176
24. L.K. Nilsson, K.R. Linderholm, G. Engberg, L. Paulson, K. Blennow, L.H. Lindström, C. Nordin, A. Karanti, P. Persson, and S. Erhardt Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia Schizophr. Res. 80 2005 315 322
25. R.L. Papke, W.R. Kem, F. Soti, G.Y. Lopez-Hernandez, and N.A. Horenstein Activation and desensitization of nicotinic alpha7-type acetylcholine receptors by benzylidene anabaseines and nicotine J. Pharmacol. Exp. Ther. 329 2009 791 807
26. V. Parikh, J. Ji, M.W. Decker, and M. Sarter Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling J. Neurosci. 30 2010 3518 3530
27. V. Parikh, K. Man, M.W. Decker, and M. Sarter Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex J. Neurosci. 28 2008 3769 3780
28. C.G. Parsons, W. Danysz, G. Quack, S. Hartmann, B. Lorenz, C. Wollenburg, L. Baran, E. Przegalinski, W. Kostowski, P. Krzascik, B. Chizh, and P.M. Headley Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization J. Pharmacol. Exp. Ther. 283 1997 1264 1275
29. R. Pellicciari, R. Rizzo, G. Costantino, M. Marinozzi, L. Amori, P. Guidetti, H.-Q. Wu, and R. Schwarcz Modulators of the kynurenine pathway of tryptophan metabolism: synthesis and preliminary biological evaluation of (S)-4-(Ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor Chem. Med. Chem. 1 2006 528 531
30. S. Potvin, E. Stip, A.A. Sepehry, A. Gendron, R. Bah, and E. Kouassi Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review Biol. Psychiatry 63 2008 801 808
31. S.J. Rousseau, I.W. Jones, I.A. Pullar, and S. Wonnacott Presynaptic alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate [3H]d-aspartate release from rat frontal cortex in vitro Neuropharmacology 49 2005 59 72
32. M. Sarter, V. Parikh, and W.M. Howe nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms Biochem. Pharmacol. 78 2009 658 667
33. M.P. Sceniak, and M.B. MacIver Cellular actions of urethane on rat visual cortical neurons in vitro J. Neurophysiol. 95 95 2006 3865 3874
34. R. Schwarcz, J.P. Bruno, P.J. Muchowski, and H.-Q. Wu Kynurenines in the mammalian brain: when physiology meets pathology Nat. Rev. Neurosci. 13 2012 465 477
35. R. Schwarcz, A. Rassoulpour, H.Q. Wu, D. Medoff, C.A. Tamminga, and R.C. Roberts Increased cortical kynurenate content in schizophrenia Biol. Psychiatry 50 2001 521 530
36. K.V. Trecartin, and D.J. Bucci Administration of kynurenine during adolescence, but not during adulthood, impairs social behavior in rats Schizophr. Res. 133 2011 156 158
37. I. Wonodi, and R. Schwarcz Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia Schizophr. Bull. 36 2010 211 218